Breakthroughs Blog

City of Hope has so many breakthroughs in cancer, diabetes and HIV/AIDS - and so many stories - that we've tailored our blog, Breakthroughs, to provide something for every reader. Whether the breakthroughs are about medical research, treatment advances or personal triumphs, they're all connected.

Niland-Joyce
City of Hope-Led Diabetes Network Receives Support from Helmsley Charitable Trust

August 15, 2017 | Katie Neith

City of Hope scientists in the Beckman Research Institute have received over $300,000 from The Leona M. and Harry B. Helmsley Charitable Trust to support scientific collaborations to fight type 1 diabetes.

Continue Reading

Biotech for Poets at City of Hope
Biotech for Poets: Simplifying the Complex

July 14, 2017 | Travis Marshall

The idea of enlisting science and technology experts to present talks about their work for layman audiences is something Will Murdoch first encountered as an undergraduate.

Continue Reading

Categories : Faculty

Joe Gold, Manufacturing Director, Center for Biomedicine and Genetics, City of Hope
'I Make Weapons': Joseph Gold, Ph.D.

July 13, 2017 | Abe Rosenberg

Joseph Gold, Ph.D., is chief overseer of a sprawling, state-of-the-art manufacturing facility cranking out mass quantities of carefully engineered stem cells aimed at curing the most dangerous and debilitating diseases of our time.

Continue Reading

Categories : Faculty

test tubes
Research Grant Roundup

July 10, 2017 | City of Hope

Review the latest City of Hope grant awardees.

Continue Reading

Categories : Faculty

Cai Roberts, Grad Student | City of Hope
Grad Student Profile: Cai Roberts

July 7, 2017 | Samantha Bonar

Graduate student Cai Roberts is exploring a novel twist on cancer treatment that targets a unique protein. The protein, called Twist, may allow cancer cells to take some devious turns within the body.

Continue Reading

Categories : Students

patel sunita 256x256
Sunita Patel Leads Impressive Slate of Grant Awardees

July 7, 2017 | Samantha Bonar

Sunita Patel, Ph.D., a neuropsychologist in the Population Sciences and Supportive Care Medicine departments at City of Hope, has received a $1.22 million grant from the American Cancer Society to test a new approach toward preventing long-term chemotherapy-related cognitive side effects.

Continue Reading

breast cancer and genes
Core Connection: Get to Know the Integrative Genomics Core

July 6, 2017 | Katie Neith

At City of Hope, the Integrative Genomics Core (IGC) provides basic science, translational and clinical researchers with high-quality, efficient, comprehensive and cost-effective genomic services using microarray and high-throughput sequencing technologies.

Continue Reading

Categories : Shared Resources

Kittles 256x256
New Hire: Rick Kittles, Ph.D.

July 6, 2017 | Samantha Bonar

Rick Kittles, Ph.D., has joined City of Hope as professor and founding director of the Division of Health Equities within the Department of Population Sciences. Kittles’ research focuses on understanding the complex issues surrounding race, genetic ancestry and disease, particularly health disparities among different ethnicities.

Continue Reading

Categories : Faculty

Malkas-Linda
Linda Malkas: Henrietta Lacks Made My Work Possible

June 30, 2017 | Linda Malkas, Ph.D.

Henrietta Lacks certainly influenced my research, and continues to do so. Her impact is great here at City of Hope, as it is around the world. I’m just one scientist whose work has been made possible by Henrietta. There are many of us who owe her a profound debt of gratitude. Internationally, the number of people who have benefited from what she left behind is impossible to calculate.

Continue Reading

robert w chen md 256x256
PD-L1 inhibition is 'effective and safe' in patients with relapsed or refractory Hodgkin lymphoma

June 29, 2017 | Katie Neith

Clinical trial results in positive outcomes for patients with relapsed or treatment-resistant disease. Hodgkin lymphoma is typically considered to be one of the most curable forms of cancer, but some with the disease relapse or find that their cancer is resistant to treatment. For patients like this, a fully human monoclonal antibody called avelumab has shown promising results in a phase 1 clinical trial for safety and efficacy.

Continue Reading

Load More
Back To Top